Communiqués Exact Sciences Corporation

Actions

EXAS

US30063P1057

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 21:00:00 20/03/2026			Varia. 5j.	Varia. 1 janv.
104,91 ^USD	+0,95 %		-.--%	+3,30 %

23/03	Les marchés américains reprennent des couleurs après la décision inattendue de Trump
23/03	Exact Sciences Corporation annonce la démission de son conseil d'administration et de ses comités, avec effet au 23 mars 2026	CI

Communiqués

17/03	Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026	BU
04/03	Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year	BU
20/02	Exact Sciences Stockholders Approve Acquisition by Abbott	BU
13/02	Exact Sciences: Q4 Earnings Snapshot	AQ
13/02	Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results	BU
03/02	Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests	BU
03/02	Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide	BU
31/12	Tel Aviv University: TAU and Google Israel Launch New Three-Year Program to Advance Core AI Research	AQ
18/12	Exact Sciences : Announces First Participant Enrolled in the CRANE Study, a Multi-Cancer Early Detection Clinical Evaluation in Japan	PU
12/12	Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect MRD Test in Early Triple-Negative Breast Cancer at SABCS	AQ
11/12	Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS	BU
24/11	Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium	BU
24/11	EXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott Laboratories	AQ
22/11	Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS	BU
10/11	Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome’s Blood-Based Colorectal Cancer Screening Tests	BU
07/11	Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test	BU
04/11	Exact Sciences to Participate in November Investor Conference	BU
03/11	Exact Sciences: Q3 Earnings Snapshot	AQ
03/11	Exact Sciences Announces Third Quarter 2025 Results	BU
27/10/25	Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps	BU
08/10/25	Exact Sciences Corp. - New Study in Journal of the National Cancer Institute Finds Cologuard Plus Provides the Most Life-Years Gained with the Fewest Colonoscopies	AQ
08/10/25	Exact Sciences Schedules Third Quarter 2025 Earnings Call	BU
07/10/25	New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies	BU
23/09/25	Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard Test	AQ
23/09/25	Exact Sciences : Latest Corporate Presentation	PU